Thursday, July 20, 2017 8:57:29 AM
“This is the culmination of almost three years of hard work and dedication from its management and shareholders. The majority shareholders and management, have successfully vacated three lawsuits, which lingered from previous management. In addition to that, the company has been diligently working over the last three months, with company counsel and OTC markets to bring the company OTC markets status current. Which is expected very soon.” stated CEO David Failla.
David Failla
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM